NERV

#3538
Minerva Neurosciences, Inc - Common Stock
4.7 5 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.75
4.89
Intervallo Annuale
1.93
12.46
Variazione giornaliera
-1.86%
Variazione Mensile
+20.25%
Variazione di 6 mesi
-26.01%
Variazione Annuale
+102.13%
Chiusura Precedente
4.8 4
Open
4.8 5
Minimo
4.7 5
Massimo
4.8 9
Volume
8
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Minerva Neurosciences, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Minerva Neurosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Minerva Neurosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Minerva Neurosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Minerva Neurosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Minerva Neurosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Minerva Neurosciences, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Minerva Neurosciences, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Minerva Neurosciences, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Minerva Neurosciences, Inc. current report, Q1 FY2026
8-K

Minerva Neurosciences, Inc. current report, Q4 FY2024

Full document

Business Context and Reporting Period

Company: Minerva Neurosciences, Inc. (NERV)
Filing Type: Form 8-K (Current Report)
Date of Report: October 8, 2024
Reporting Period: Event-based report regarding Nasdaq listing compliance status.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The report focuses exclusively on regulatory compliance regarding the company's stock listing status.

Material Changes and Events

  • Delisting Notice: On October 8, 2024, the Company received a second written notice from Nasdaq stating that its securities will be delisted from The Nasdaq Capital Market due to continued non-compliance with Listing Rule 5550(b)(2).
  • Compliance Issue: The Company failed to maintain a minimum Market Value of Listed Securities of $35 million for 31 consecutive business days, a requirement first notified on April 10, 2024.
  • Deadline Missed: The Company did not regain compliance by the October 7, 2024 deadline.

Outlook, Management Commentary, and Risks

  • Management Action: The Company intends to timely request a hearing before a Nasdaq Hearings Panel. This request will stay any suspension or delisting action pending the hearing outcome.
  • Potential Extension: The Hearings Panel has discretion to grant a further extension of up to April 5, 2025.
  • Risks and Contingencies: There is no assurance that the Panel will grant an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.

Investor Verification Checklist

  • Verify the current market capitalization and stock price to assess the likelihood of regaining the $35 million Market Value of Listed Securities threshold.
  • Monitor the status of the hearing request with the Nasdaq Hearings Panel and any subsequent rulings.
  • Review the Company's capital raising plans or strategic initiatives intended to address the market value deficiency.
  • Check for any subsequent filings regarding the outcome of the hearing or potential transfer to an alternative trading venue.

Notizie